Holen Sie sich die Stockscreener-App
6.73
2.44%
0.16
Handel nachbörslich:
6.73
Kura Oncology Inc Aktie (KURA) Neueste Nachrichten
Kura Oncology Stockholders Approve Equity Plan Amendment - TipRanks
KURA Stock Rises More Than 15% This Past Week: Here's Why - sharewise
Kura Oncology Reports Inducement Grants Under Nasdaq Listing Rul - GuruFocus
Kura Oncology (KURA) Grants Stock Options to New Employees | KUR - GuruFocus
Kura Oncology Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4) - The Manila Times
Kura Oncology Reports Inducement Grants Under Nasdaq Listing Rule 5635(C)(4) - marketscreener.com
Kura Oncology Expands Cancer Research Team with Strategic Stock Options for 5 Key New Hires - Stock Titan
Kura Oncology’s (KURA) “Market Outperform” Rating Reaffirmed at JMP Securities - Defense World
Kura Oncology at Jefferies Conference: Strategic Advancements in AML By Investing.com - Investing.com Canada
Two Sigma Investments LP Sells 42,120 Shares of Kura Oncology, Inc. (NASDAQ:KURA) - Defense World
Rising Leaders 2025: Kura Oncology’s Mollie Leoni On Setting Precedent, Not Following It - insights.citeline.com
Nuveen Asset Management LLC Lowers Stock Position in Kura Oncology, Inc. (NASDAQ:KURA) - Defense World
Transcript : Kura Oncology, Inc. Presents at American Society of Clinical Oncology Annual Meeting 2025, Jun-02-2025 06 - marketscreener.com
Kura Oncology Drug’s Data at ASCO Support FDA Filing Now Under Priority Review for Leukemia - MedCity News
KURA: Optimism for Kura Oncology's Menin Inhibitor Grows with FDA Priority Review | KURA Stock News - GuruFocus
Cantor Fitzgerald reiterates overweight rating for Kura Oncology stock By Investing.com - Investing.com Nigeria
Kura Oncology reports positive trial results for AML treatment By Investing.com - Investing.com South Africa
Kura Oncology at ASCO: Strategic Moves in AML Treatment By Investing.com - Investing.com Canada
Kura Oncology reports positive trial results for AML treatment - Investing.com Australia
KURA: Promising Results for Kura Oncology's AML Therapy at ASCO Meeting | KURA Stock News - GuruFocus
Kura Oncology and Kyowa Kirin Report Positive Pivotal Ziftomenib - GuruFocus
Kura Oncology and Kyowa Kirin Report Positive Pivotal Ziftomenib Monotherapy Data at 2025 ASCO Annual Meeting | KURA Stock News - GuruFocus
Kura Oncology and Kyowa Kirin Report Positive Pivotal Ziftomenib Monotherapy Data at 2025 ASCO Annual Meeting - Yahoo Finance
FDA Grants Priority Review for Kura Oncology, Inc. (KURA) and Kyowa Kirin’s Ziftomenib - Insider Monkey
H.C. WAINWRIGHT REITERATES BUY RATING ON KURA ONCOLOGY STOCK By Investing.com - Investing.com Nigeria
Kura Oncology, Kyowa Get FDA Acceptance, Priority Review of New Drug Application for Ziftomenib - marketscreener.com
ProShare Advisors LLC Has $210,000 Position in Kura Oncology, Inc. (NASDAQ:KURA) - Defense World
Kura Oncology (KURA) Awaits FDA Decision on New Leukemia Treatme - GuruFocus
Kura Oncology (KURA) Awaits FDA Decision on New Leukemia Treatment | KURA Stock News - GuruFocus
Kura Oncology and Kyowa Kirin Announce FDA Acceptance and Priori - GuruFocus
Kura Oncology and Kyowa Kirin Announce FDA Acceptance of New Drug Application for Ziftomenib in Relapsed or Refractory AML with NPM1 Mutation - Nasdaq
FDA Fast-Tracks First-Ever Menin Inhibitor for AML: Kura's Breakthrough Drug Heads for November Decision - Stock Titan
Bank of America Corp DE Has $2.83 Million Stock Holdings in Kura Oncology, Inc. (NASDAQ:KURA) - Defense World
Kura Oncology, Inc. (NASDAQ:KURA) Shares Acquired by MIRAE ASSET GLOBAL ETFS HOLDINGS Ltd. - Defense World
Deutsche Bank AG Buys 21,135 Shares of Kura Oncology, Inc. (NASDAQ:KURA) - Defense World
Kura Oncology, Inc. (NASDAQ:KURA) Receives Consensus Recommendation of “Moderate Buy” from Brokerages - Defense World
Kura Oncology’s SWOT analysis: ziftomenib success key to stock’s future By Investing.com - Investing.com Canada
Kura Oncology’s SWOT analysis: ziftomenib success key to stock’s future - Investing.com India
Kura Oncology (NASDAQ:KURA) Trading Down 4.7% – Time to Sell? - Defense World
Cantor Fitzgerald maintains Overweight on Kura Oncology stock - Investing.com Australia
Cantor Fitzgerald maintains Overweight on Kura Oncology stock By Investing.com - Investing.com South Africa
Kura Oncology, Inc. (KURA) and Kyowa Kirin to Present Promising Ziftomenib Data at ASCO 2025 - MSN
Jane Street Group LLC Sells 25,869 Shares of Kura Oncology, Inc. (NASDAQ:KURA) - Defense World
Kura Oncology to present trial results for AML treatment - Investing.com Australia
Kura Oncology to present trial results for AML treatment By Investing.com - Investing.com Nigeria
Kura Oncology and Kyowa Kirin Announce Pivotal Monotherapy Data for Ziftomenib in Oral Presentation at the 2025 ASCO Annual Meeting | KURA Stock News - GuruFocus
Kura Oncology and Kyowa Kirin Announce KOMET-001 Trial Results for Ziftomenib in R/R NPM1-m AML Selected for ASCO Presentation - Nasdaq
Kura Oncology and Kyowa Kirin Announce Pivotal Monotherapy Data for Ziftomenib in Oral Presentation at the 2025 ASCO Annual Meeting - The Manila Times
Northern Trust Corp Sells 20,239 Shares of Kura Oncology, Inc. (NASDAQ:KURA) - Defense World
Kura Oncology to Participate in Three Upcoming Investor Conferen - GuruFocus
Kura Oncology to Participate in Three Upcoming Investor Conferences - The Manila Times
Kura Oncology, Inc. to Participate in Upcoming Investor Conferences in May and June 2025 - Nasdaq
Kura Oncology Sets Triple Conference Schedule: Goldman Sachs, Jefferies, and TD Cowen Healthcare Events - Stock Titan
Kura Oncology (NASDAQ:KURA) Price Target Lowered to $30.00 at Mizuho - Defense World
KURA: Mizuho Maintains Rating but Lowers Price Target for Kura O - GuruFocus
Kura Oncology (KURA) Target Price Adjusted by Mizuho | KURA Stoc - GuruFocus
Balyasny Asset Management L.P. Has $144,000 Stock Position in Kura Oncology, Inc. (NASDAQ:KURA) - Defense World
0.00%
2.33%
In Yahoo öffnen
|
In Google öffnen
|
In Finviz öffnen
|
In MarketWatch öffnen
|
Öffnen Sie in EDGAR
|
Offen in Reuters
Kapitalisierung:
|
Volumen (24h):